MGTA - Biogen's NURTURE Data And Other News: The Good Bad And Ugly Of Biopharma
Biogen Reports Positive Data from Landmark NURTURE Study
Biogen Inc. (BIIB) reported new data from NURTURE which included nearly a year of additional follow-up for NURTURE study participants. It is the longest study of pre-symptomatic patients with spinal muscular atrophy. New data shows that in infants genetically diagnosed with SMA, early and sustained treatment with SPINRAZA for up to 4.8 years enabled unprecedented survival.
As of February 2020, all 25 patients treated were alive and remained free of permanent ventilation. All children who achieved the motor milestone of being able to walk independently,